Zheng L, Ji YY, Dai YC, Wen XL, Wu SC. Network pharmacology and molecular docking reveal zedoary turmeric-trisomes in Inflammatory bowel disease with intestinal fibrosis. World J Clin Cases 2022; 10(22): 7674-7685 [PMID: 36158488 DOI: 10.12998/wjcc.v10.i22.7674]
Corresponding Author of This Article
Shi-Cheng Wu, Department of Proctology, Gansu Academy of Traditional Chinese Medicine, Gansu Hospital of Traditional Chinese Medicine, No. 418 Guazhou Road, Qilihe District, Lanzhou 730050, Gansu Province, China. 594068860@qq.com
Research Domain of This Article
Mathematical & Computational Biology
Article-Type of This Article
Clinical and Translational Research
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 6, 2022; 10(22): 7674-7685 Published online Aug 6, 2022. doi: 10.12998/wjcc.v10.i22.7674
Network pharmacology and molecular docking reveal zedoary turmeric-trisomes in Inflammatory bowel disease with intestinal fibrosis
Lie Zheng, Yong-Yi Ji, Yan-Cheng Dai, Xin-Li Wen, Shi-Cheng Wu
Lie Zheng, Department of Gastroenterology, Shaanxi Hospital of Traditional Chinese Medicine, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi’an 730000, Shaanxi Province, China
Yong-Yi Ji, Department of Neurology, Xi’an Hospital of Traditional Chinese Medicine, Xi’an 710021, Shaanxi Province, China
Yan-Cheng Dai, Department of Gastroenterology, Shanghai Traditional Chinese Medicine Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China
Xin-Li Wen, Department of Gastroenterology, Shaanxi Hospital of Traditional Chinese Medicine, Xi’an 710003, Shaanxi Province, China
Shi-Cheng Wu, Department of Proctology, Gansu Academy of Traditional Chinese Medicine, GanSu Hospital of Traditional Chinese Medicine, Lanzhou 730050, Gansu Province, China
Author contributions: Zheng L, Ji YY, Dai YC and Wu SC reviewed the literature and prepared the manuscript, performed to the writing and revising of the manuscript; Zheng L and Wen XL contributed to design this work, and performed overall supervision; Zheng L wrote and revised the paper; all authors approved the final manuscript.
Supported byGeneral Research of Xi’an Science and Technology Planning Project, No. 2022JH-YBYJ-0265; Shaanxi Province Natural Science Basic Research Program-General Project, No: 2019JM-580 and 2021SF-314; Project of Shaanxi Administration of Traditional Chinese Medicine, No. 2019-ZZ-JC010; and Shaanxi Provincial Hospital of Traditional Chinese Medicine, No. 2021-07, 2018-04.
Institutional review board statement: Since this article is a molecular mechanism study of network pharmacology and does not involve animal experiments or clinical experiments, it does not require the approval of an ethics committee.
Conflict-of-interest statement: All authors report no relevant conflict of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shi-Cheng Wu, Department of Proctology, Gansu Academy of Traditional Chinese Medicine, Gansu Hospital of Traditional Chinese Medicine, No. 418 Guazhou Road, Qilihe District, Lanzhou 730050, Gansu Province, China. 594068860@qq.com
Received: March 16, 2022 Peer-review started: March 16, 2022 First decision: April 11, 2022 Revised: May 5, 2022 Accepted: June 30, 2022 Article in press: June 30, 2022 Published online: August 6, 2022 Processing time: 127 Days and 20.4 Hours
ARTICLE HIGHLIGHTS
Research background
Intestinal fibrosis is a serious complications of inflammatory bowel disease (IBD), but there is no effective drug treatment. Therefore, it is important to find drug treatments with fewer side effects.
Research motivation
To provide an objective basis for zedoary turmeric-trisomes in the treatment of IBD with intestinal fibrosis.
Research objectives
To investigate the use of network pharmacology and molecular docking technology in analyzing the effective components and mechanism of zedoary turmeric-trisomes in the treatment of IBD with intestinal fibrosis.
Research methods
The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform were used to extract the active components and action targets of zedoary turmeric-trisomes.
Research results
The protein-protein interaction network showed that the core therapeutic targets included JUN, MAPK14, CASP3, AR, and PTGS2. The GO enrichment analysis identified 759 items, and the KEGG enrichment analysis yielded 52 items. Molecular docking showed that the compound bonded with the target through hydrogen bond interactions and exhibited good docking activity.
Research conclusions
This study identified the potential mechanism of action of zedoary turmeric-trisomes in the treatment of IBD using network pharmacology and molecular docking technology.
Research perspectives
TCM has a potential mechanism in the treatment of IBD with intestinal fibrosis.
